Simon Zhou
Overview
Explore the profile of Simon Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu H, Li Y, Piasecki J, Hosseyni D, Yan Z, Liu X, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836430
Purpose: Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), was evaluated in relapsed/refractory multiple myeloma (RRMM) patients in the EVOLVE phase 1/2 study (NCT03430011). We...
2.
Sun D, Macedonia C, Chen Z, Chandrasekaran S, Najarian K, Zhou S, et al.
J Med Chem
. 2024 Sep;
67(18):16035-16055.
PMID: 39253942
Despite implementing hundreds of strategies, cancer drug development suffers from a 95% failure rate over 30 years, with only 30% of approved cancer drugs extending patient survival beyond 2.5 months....
3.
Gaudy A, Laille E, Bailey R, Zhou S, Skikne B, Beach C
Clin Pharmacol Ther
. 2023 Jul;
114(4):845-852.
PMID: 37422689
Oral azacitidine (oral-AZA) maintenance is approved for adults with acute myeloid leukemia (AML) in remission post-intensive chemotherapy, not proceeding to hematopoietic stem cell transplantation. This study aimed to develop a...
4.
Cheng Y, Gaudy A, Liu L, Ye Y, Thomas M, Xue Y, et al.
Clin Pharmacol Drug Dev
. 2023 Apr;
12(8):819-825.
PMID: 37079714
Iberdomide is an orally available cereblon-modulating agent being developed for the treatment of hematologic malignancies and autoimmune-mediated diseases. To assess the potential concentration-QTc relationship in humans and to ascertain or...
5.
Johansson K, Gagnon J, Zhou S, Fassett M, Schroeder A, Kageyama R, et al.
bioRxiv
. 2023 Mar;
PMID: 36993421
The miR-15/16 family is a highly expressed group of tumor suppressor miRNAs that target a large network of genes in T cells to restrict their cell cycle, memory formation and...
6.
Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, et al.
Clin Pharmacol
. 2023 Mar;
15:9-19.
PMID: 36880014
Introduction: Iberdomide, a novel cereblon modulator (CELMoD), is currently under clinical investigation for hematology indications. To evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of iberdomide and its...
7.
Connarn J, Witjes H, van Zutphen-van Geffen M, de Greef R, Campbell T, Hege K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(11):1687-1697.
PMID: 36794354
Idecabtagene vicleucel (ide-cel; bb2121) is a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This...
8.
Cheng Y, Hong K, Chen N, Yu X, Peluso T, Zhou S, et al.
EJHaem
. 2022 Sep;
3(3):815-827.
PMID: 36051011
Early prognosis of clinical efficacy is an urgent need for oncology drug development. Herein, we systemically examined the quantitative approach of tumor growth inhibition (TGI) and survival modeling in the...
9.
Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, et al.
Cancer Chemother Pharmacol
. 2022 Aug;
90(4):325-334.
PMID: 36001108
Purpose: Fedratinib is an orally administered Janus kinase (JAK) 2-selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. In vitro, fedratinib is predominantly...
10.
Cheng Y, Xue Y, Chen L, Masin M, Maciag P, Peluso T, et al.
Br J Clin Pharmacol
. 2022 Aug;
89(1):316-329.
PMID: 35981078
Aims: A parent-metabolite population pharmacokinetic (popPK) model of iberdomide and its pharmacologically active metabolite (M12) was developed and the influence of demographic and disease-related covariates on popPK parameters was assessed...